Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 170
- Registration Number
- NCT00001832
- Locations
- ๐บ๐ธ
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00001564
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 36
- Registration Number
- NCT00001474
- Locations
- ๐บ๐ธ
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 80
- Registration Number
- NCT00001357
- Locations
- ๐บ๐ธ
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 49
- Registration Number
- NCT00001430
- Locations
- ๐บ๐ธ
National Cancer Institute (NCI), Bethesda, Maryland, United States
Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00001440
- Locations
- ๐บ๐ธ
National Cancer Institute (NCI), Bethesda, Maryland, United States
Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 100
- Registration Number
- NCT00001409
- Locations
- ๐บ๐ธ
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.